Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01212159 · ClinicalTrials.gov registry record · Phase 4

Telephone Based Management of Hyperlipidemia

A Phase 4 study of Hyperlipidemia, sponsored by Temple University.

Completed
Registry status
Phase 4
Development phase
70
Enrollment target
1
Study location

NCT01212159 is a Phase 4 study of Hyperlipidemia that has completed, run by Temple University. The registered enrollment target is 70 participants, below the 406-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01212159, a Phase 4 study of Hyperlipidemia, has completed, sponsored by Temple University.

COMPLETED
Registry status
Phase 4
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to demonstrate that systematic self measurement of blood lipids reduces LDL cholesterol more effectively than standard care. The hypothesis is that cholesterol lowering medication adherence will be improved with self monitoring and reporting of frequent blood lipids and the percentage of patients achieving LDL goal will be greater than without home monitoring.

Conditions Studied

Interventions

  • DEVICE Self Monitoring Lipid Analyzer

Study Locations (1)

Pennsylvania

  • Temple University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2010-11
Est. Completion 2015-08
Phase Phase 4

Sponsor

Temple University

163 total trials

What the Registry Record Tells You About NCT01212159

The ClinicalTrials.gov registry entry for NCT01212159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 406-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (83% lower). The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 1 intervention - of which Self Monitoring Lipid Analyzer is the first listed.

NCT01212159 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01212159 about?

NCT01212159 is a clinical study titled "Telephone Based Management of Hyperlipidemia". The purpose of the study is to demonstrate that systematic self measurement of blood lipids reduces LDL cholesterol more effectively than standard care. The hypothesis is that cholesterol lowering medication adherence will be improved with self monitoring and reporting of frequent blood lipids and t...

What is the current status of trial NCT01212159?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2010-11. Estimated completion is 2015-08.

What conditions does trial NCT01212159 study?

This clinical trial studies the following conditions: Hyperlipidemia.

What interventions are being tested in trial NCT01212159?

The interventions under investigation include: Self Monitoring Lipid Analyzer (DEVICE).

Who is sponsoring clinical trial NCT01212159?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01212159 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperlipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.